(S1 (S (S (VP (VBG Killing) (NP (NN tumor) (NNS cells)) (PP (IN through) (NP (PRP$ their) (NN surface) (JJ beta-LRB-2-RRB--microglobulin) (CC or) (JJ major) (NN histocompatibility) (NN complex) (NN class) (NN I) (NNS molecules))))) (. .)))
(S1 (S (S (NP (VBN Targeted) (JJ antibody-based) (NN therapy)) (VP (VBZ has) (VP (VBN been) (VP (VBN used) (ADVP (RB successfully)) (S (VP (TO to) (VP (VB treat) (NP (NNS cancers))))))))) (. .)))
(S1 (S (S (NP (JJ Recent) (NNS studies)) (VP (VBP have) (VP (VBN demonstrated) (SBAR (IN that) (S (NP (NP (NN tumor) (NNS cells)) (VP (VBN treated) (PP (IN with) (NP (NP (NNS antibodies)) (ADJP (JJ specific) (PP (IN for) (NP (NP (NP (NN beta-LRB-2-RRB--microglobulin)) (PRN (-LRB- -LRB-) (NP (NN beta-LRB-2-RRB-M)) (-RRB- -RRB-))) (CC or) (NP (NP (JJ major) (NN histocompatibility) (NN complex) (-LRB- -LRB-) (NN MHC) (-RRB- -RRB-) (NN class)) (NN I) (NNS molecules))))))))) (VP (VBP undergo) (NP (NN apoptosis)) (ADVP (ADVP (FW in) (FW vitro)) (CC and) (ADVP (FW in) (FW vivo)) (PRN (-LRB- -LRB-) (NP (NN mouse) (NNS models)) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (S (NP (NP (NNS Antibodies)) (PP (IN against) (NP (NP (NN beta-LRB-2-RRB-M)) (CC or) (NP (NN MHC) (NN class) (CD I))))) (VP (VBP induce) (NP (NN tumor) (NN cell) (NN apoptosis)) (PP (IN by) (S (VP (VP (LST (LS 1) (-RRB- -RRB-)) (VP (VP (VBG recruiting) (NP (NN MHC) (NN class) (CD I) (NNS molecules)) (PP (TO to) (NP (NN lipid) (NNS rafts)))) (CC and) (VP (VBG activating) (NP (NP (NN LYN) (NN kinase)) (CC and) (NP (NP (DT the) (JJ signal-transducing) (NN enzyme) (NN phospholipase) (JJ C-gamma2-dependent) (NN c-Jun) (JJ N-terminal) (NN kinase)) (NN signaling) (NN pathway)))))) (CC and) (VP (LST (LS 2) (-RRB- -RRB-)) (VP (VP (VBG expelling) (NP (NP (NP (NP (NN interleukin) (CD 6)) (CC and) (NP (JJ insulin-like) (NN growth) (NN factor) (CD 1))) (NNS receptors)) (PP (RP out) (PP (IN of) (NP (NN lipid) (NNS rafts)))))) (CC and) (VP (VBG inhibiting) (NP (NP (DT the) (ADJP (NN growth) (CC and) (NN survival) (JJ factor-induced)) (NN activation)) (PP (IN of) (NP (NP (NP (DT the) (NN phosphatidylinositol) (NN 3-kinase/Akt)) (CC and) (NP (JJ extracellular) (JJ signal-related) (NN kinase))) (NNS pathways)))))))))))) (. .)))
(S1 (S (S (S (ADVP (RB Consequently)) (, ,) (NP (JJ mitochondrial) (NN integrity)) (VP (VBZ is) (VP (VBN compromised)))) (, ,) (CC and) (S (NP (DT the) (JJ caspase-9-dependent) (NN cascade)) (VP (VBZ is) (VP (VBN activated) (PP (IN in) (NP (JJ treated) (NN tumor) (NNS cells))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (SBAR (IN although) (S (NP (NP (NN beta-LRB-2-RRB-M)) (CC and) (NP (NN MHC) (NN class) (CD I))) (VP (VBP are) (VP (VBN expressed) (PP (IN on) (NP (NP (JJ normal) (JJ hematopoietic) (NNS cells)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (NP (DT a) (JJ potential) (NN safety) (NN concern))))))))))) (, ,) (NP (DT the) (JJ monoclonal) (NNS antibodies)) (VP (VP (VBD were) (ADJP (JJ selective) (PP (TO to) (NP (NN tumor) (NNS cells))))) (CC and) (VP (VBD did) (RB not) (VP (NN damage) (NP (JJ normal) (NNS cells)) (UCP (ADVP (FW in) (FW vitro)) (CC or) (PP (IN in) (NP (JJ human-like) (NN mouse) (NNS models)))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS findings)) (VP (VBP suggest) (SBAR (IN that) (S (S (VP (VBG targeting) (NP (NP (NN beta-LRB-2-RRB-M)) (CC or) (NP (NN MHC) (NN class) (CD I))) (PP (IN by) (S (VP (VBG using) (NP (NP (NNS antibodies)) (CC or) (NP (JJ other) (NNS agents)))))))) (VP (VBZ offers) (NP (NP (DT a) (ADJP (ADJP (JJ potential)) (ADJP (JJ therapeutic))) (NN approach)) (PP (IN for) (NP (JJ beta-LRB-2-RRB-M/MHC) (NN class) (NN I-expressing) (NNS malignancies))))))))) (. .)))
(S1 (S (NP (NP (NN Cancer) (NN 2010)) (. .))))
(S1 (S (S (LST (-LRB- -LRB-) (LS c) (-RRB- -RRB-)) (NP (NN 2010)) (NP (NNP American) (NN Cancer) (NNP Society))) (. .)))
